INJE PharmacoGenomics Research Center

· Oh MK, Lee HC, Kim SU, Kim BT, Song GS, Shin JG, Ghim JL

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects (cPMTb)

Transl Clin Pharmacol. 31(2):114-123 / 2023.06 [LINK]

Impact of Criterion Versus Norm-Referenced Assessment on the Quality of Life in Korean Medical Students (cPMTb)

J Korean Med Sci. 38(17):e133 / 2023.05 [LINK]

· Kim RH, Jayanti RP, Lee HY, Kim HK, Kang JY, Park IN, Kim JH, Oh JY, Kim HW, Lee HY, Ghim JL, Ahn SZ, Long NP, Cho YS, Shin JG, On Behalf Of The cPMTb

Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance (cPMTb)

Front Pharmacol. 26:14:1116226 / 2023.05 [LINK]

· Lee MH, Yoon SK, Kim HS, Cho YS, Han SP, Lee SH, Bae KS, Jung JN, Hong SH, Lim HS

Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers (cPMTb)

Drug Des Devel Ther. 12:17:1107-1114 / 2023.04 [LINK]

· Yen NTH, Oh JH, Anh NTV, Le QV, Park SM, Park YJ, Cho YS, Moon KS, Nguyen HT, Shin JG, Long NP

Systems-level multi-omics characterization provides novel molecular insights into indomethacin toxicity (cPMTb)

Chem Biol Interact. 25:375:110430 / 2023.04 [LINK]

· Cho HY, Ahn SZ, Cho YS, Seo SK, Kim DH, Shin JG, Lee SJ

CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARャ Receptor (cPMTb)

Pharmaceuticals(Basel). 16(4):593 / 2023.04 [LINK]

· Ahn SZ

The impending impacts of large language models on medical education (cPMTb)

Korean J Med Educ. 35(1):103-107 / 2023.03 [LINK]

· Long NP, Kang JS, Kim HM

Caenorhabditis elegans: a model organism in the toxicity assessment of environmental pollutants (cPMTb)

Environ Sci Pollut Res Int. 30(14):39273-39287 / 2023.03 [LINK]

· Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Lius EE, Yuliwulandari R, Hoa PQ, Phat NK, Thu VTA, Anh NK, Ahn SZ, Long NP, Cho YS, Shin JG

Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis (cPMTb)

Tuberculosis (Edinb). 139:102325 / 2023.03 [LINK]

· Thu VTA, Dat LD, Jayanti RP, Trinh HKT, Hung TM, Cho YS, Long NP, Shin JG

Advancing personalized medicine for tuberculosis through the application of immune profiling (cPMTb)

Front Cell Infect Microbiol. 10:13:1108155 / 2023.02 [LINK]

Publications

Product